

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/015653 A1

(43) International Publication Date
18 January 2024 (18.01.2024)

(51) International Patent Classification:

C07K 1/02 (2006.01) C12N 15/63 (2006.01)
C12N 9/10 (2006.01) C12N 15/67 (2006.01)
C12N 15/11 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2023/066524

(22) International Filing Date:

02 May 2023 (02.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/359,871 10 July 2022 (10.07.2022) US

(71) Applicant: **MBRACE THERAPEUTICS, INC.**

[US/US]; 4660 La Jolla Village Drive, Suite 950, San
Diego, California 92121 (US).

(72) Inventors: **WU, Yongjian**; MBrace Therapeutics, Inc.,

4660 La Jolla Village Drive, Suite 950, San Diego, Cali-
fornia 92121 (US). **STAQUICINI, Fernanda I.**; MBrace
Therapeutics, Inc., 4660 La Jolla Village Drive, Suite 950,
San Diego, California 92121 (US). **CHEN, Isan**; MBrace
Therapeutics, Inc., 4660 La Jolla Village Drive, Suite 950,
San Diego, California 92121 (US).

(74) Agent: **HALLORAN, Patrick** et al.; 80 M Street SE, 1st

Floor, Washington, District of Columbia 20003 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CELL-FREE METHODS OF RECOMBINANT ANTIBODY PRODUCTION

(57) Abstract: Provided herein are methods and cell-free systems for production of a recombinant antibody in which the antibody is directed against a target protein that is natively expressed as an intracellular protein. Also provided herein are modified cell-free systems for use in such methods in which the modified system is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

WO 2024/015653 A1